Dr Shu-Qiang Yuan speaks to ecancer about the NEOSUMMIT-01 trial.

The NEOSUMMIT-01 trial shows that adding the PD-1 antibody toripalimab to perioperative chemotherapy significantly improves survival in patients with locally advanced, resectable gastric or gastroesophageal junction cancer.

He says that after 3 years, event-free survival was 74.7% with toripalimab plus chemotherapy versus 56.2% with chemotherapy alone (HR 0.52, P=0.047), and overall survival was 81.3% versus 72.2% (HR 0.45, P=0.031).

These results highlight toripalimab combined with chemotherapy as a promising perioperative strategy for improving long-term outcomes in this patient population.